References
- Conter V, Aricò M, Basso G, . Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia 2010;24:255–264.
- Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 200612;354:166–178.
- Pession A, Rondelli R, Basso G, .Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols; AML Strategy & Study Committee of the Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP). Leukemia 2005;19:2043–2053.
- Creutzig U, Zimmermann M, Ritter J, . Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 2005;19:2030–2042.
- Uderzo C, Dini G, Locatelli F, . Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies. Haematologica 2000;85(11 Suppl.):47–53.
- Zwaan CM, Reinhardt D, Zimmerman M, . International BFM Study Group on Paediatric AML Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study. Br J Haematol 2010;148:768–776.
- Sander A, Zimmermann M, Dworzak M, . Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials. Leukemia 2010;24:1422–1428.
- Paganin M, Zecca M, Fabbri G, . Minimal residual disease is an important predictive factor of outcome in children with relapsed “high-risk” acute lymphoblastic leukemia. Leukemia 2008;22:2193–2200.
- Zhenchuk A, Lotfi K, Juliusson G, . Mechanisms of anti-cancer action and pharmacology of clofarabine. Biochem Pharmacol 2009;78:1351–1359.
- Jeha S, Gandhi V, Chan KW, . Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 2004;103:784–789.
- Kantarjian H, Gandhi V, Kozuch P, . Phase I clinical and pharmacologic study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003;21:1167–1173.
- Kantarjian H, Gandhi V, Cortes J, . Phase 2 clinical and pharmacological study of clofarabine in patients with refractory or relapsed leukemia. Blood 2003;102:2379–2386.
- Jeha S, Gaynon P, Razzouk BI, . Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 2006;24:1917–1923.
- Jeha S, Razzouk B, Rytting M, . Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Oncol 2009;27:4392–4397.
- Hijiya N, Thomson B, Isakoff MS, . Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood 2011;118:6043–6049.
- Hijiya N, Gaynon P, Barry E, . A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia 2009;23:2259–2264.
- Locatelli F, Testi AM, Bernardo ME, . Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multi relapsed acute lymphoblastic leukemia. Br J Haematol 2009;147:371–378.
- Stam RW, den Boer ML, Meijerink JP, . Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood 2003;101:1270–1276.